CRNX Crinetics Pharmaceuticals

Crinetics Pharmaceuticals to Participate in December Investor Conferences

Crinetics Pharmaceuticals to Participate in December Investor Conferences

SAN DIEGO, Nov. 23, 2020 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX), today announced that company management will participate in the following conferences in the month of December. Please see additional details below:  

Evercore ISI 3rd Annual HealthCONx Conference
Date:   Thursday, December 3rd, 2020
Time:   1:00 - 1:45 pm ET in Track 1
Panel:   Easy Pills to Swallow: Oral Drugs for Large Endo Markets
Presenter:   Dr. Scott Struthers, Founder & CEO
   
Piper Sandler's 32nd Annual Healthcare Conference
Date:   Tuesday - Thursday, December 1st - 3rd, 2020
Time:   On demand
Presenter:   , Founder & CEO, and , Chief Medical Officer
Webcast:   Pre-recorded fireside chats are available for the annual on the Events section on the Company’s website as well as on the Piper Sandler conference website.

About Crinetics Pharmaceuticals 

 is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company’s lead product candidate, , is an oral selective nonpeptide somatostatin receptor type 2 biased agonist for the treatment of acromegaly, an orphan disease affecting more than 25,000 people in the United States. Crinetics plans to advance paltusotine into a Phase 3 program in acromegaly and a Phase 2 trial for the treatment of carcinoid syndrome associated with NETs in 2021. The company is also developing , an oral nonpeptide somatostatin receptor type 5 (SST5) agonist for congenital hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of and other diseases of excess ACTH. All of the company’s drug candidates are new chemical entities resulting from in-house drug discovery efforts and are wholly owned by the company. For more information, please visit .

Contacts:

Marc Wilson

Chief Financial Officer



(858) 450-6464

Investors / Media:

Corey Davis

LifeSci Advisors



(212) 915-2577

Aline Sherwood

Scienta Communications



(312) 238-8957



EN
23/11/2020

Underlying

CRNXCrinetics Pharmaceuticals

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Crinetics Pharmaceuticals

 PRESS RELEASE
Free
CRNX Crinetics Pharm...

Crinetics Pharmaceuticals Announces August 2025 Inducement Grants Unde...

Crinetics Pharmaceuticals Announces August 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) today announced that on August 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 75,850 shares of its common stock and granted an aggregate of 53,400 restricted stock unit (“RSU”) awards to 27 new non-executive employees, in each case, under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement ...

August 11, 2025 1 EN
 PRESS RELEASE
Free
CRNX Crinetics Pharm...

Crinetics Pharmaceuticals Reports Second Quarter 2025 Financial Result...

Crinetics Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update       Regulatory Interactions and Commercial, Medical and Corporate Preparations On-Track for PALSONIFY™ (paltusotine) New Drug Application with September 25, 2025 PDUFA Date       Continued Progress on the Global Development Program for Atumelnant Across Multiple Trials, Including the BALANCE-CAH Phase 2/3 Study for the Treatment of Children with Congenital Adrenal Hyperplasia Expected to Initiate this Year       $1.2B in Cash, Cash Equivalents, and Investment Securities as of June 30, 2...

August 7, 2025 1 EN
 PRESS RELEASE
Free
CRNX Crinetics Pharm...

Crinetics to Present New Long-Term Data Demonstrating Durable Control ...

Crinetics to Present New Long-Term Data Demonstrating Durable Control of Once-Daily, Oral PALSONIFY™ (Paltusotine) in Acromegaly at ENDO 2025 Data show that PALSONIFY was well tolerated and IGF-1 levels remained stably controlled during long-term open label extensions of PATHFNDR-1 and PATHFNDR-2 studies Additional PALSONIFY presentations demonstrate reductions in patient-reported symptom burden, including both symptom severity and rates of symptom flares SAN DIEGO, July 13, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) today announced new data from its clinical development program e...

July 13, 2025 1 EN
 PRESS RELEASE
Free
CRNX Crinetics Pharm...

Crinetics Pharmaceuticals to Report Second Quarter 2025 Financial Resu...

Crinetics Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025 SAN DIEGO, July 11, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) today announced that it will report second quarter 2025 financial results on Thursday, August 7, 2025 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update. Conference Call & Webcast Thursday, August 7 @ 4:30 p.m. ET Domestic: 1 833-470-1428International: 1 404-975-4839Access Code: 899803    Webcast: Participants can use the dial-in number...

July 11, 2025 1 EN
 PRESS RELEASE
Free
CRNX Crinetics Pharm...

Crinetics Pharmaceuticals Announces July 2025 Inducement Grants Under ...

Crinetics Pharmaceuticals Announces July 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, July 10, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) today announced that on July 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 102,350 shares of its common stock and granted an aggregate of 77,875 restricted stock unit (“RSU”) awards to 46 new non-executive employees, in each case, under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement Pla...

July 10, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch